⚠ Tool for educational and informational purposes only — not investment advice or a recommendation to buy or sell. Investing carries risk of capital loss. Read the full disclaimer.
MBRX — Moleculin Biotech, Inc.
Last scan (Sept. 8, 2026): price $0.71, RSI 40.36, relative volume 0.93x, MACD ⚪ No, score 51.55.
It's trading below its 200-day average (weak underlying trend), with an RSI of 40.36. The price just broke its 20-day high, though the MACD doesn't confirm the move yet. The analysts' average target price implies +1590.1% upside — one of the score's strongest signals.
Price chart
MBRX
Price: $0.77 · RSI (14): 46.97 · Rel. volume: 0.1x · Breakout: No
- Current price: ($0.77) — solid white line — the latest available closing price.
- Target price: ($12.0) — dashed green line — average 12-month target price from analysts covering the stock.
- Quarter low: ($0.73) — dotted orange line — the lowest price over the last ~3 months, as a recent support reference.
You can zoom by dragging a rectangle over the chart, or with your mouse wheel. Double-click to reset the view.
What analysts say
MBRX
Moleculin Biotech, Inc.
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia…
- Buy 3
- Hold 0
- Sell 0
Average target price: $12.0 (+1452.2% vs. current price) · range $2.0 – $31.0
Healthy Moderate Attention No data
Total market value of the company (price × shares outstanding).
P/E (trailing): compares the stock's price with its earnings per share over the last 12 months — how many times that earning is being paid for.
Low: the market pays little for each dollar of earnings. Could be a value opportunity, or a sign the market expects little growth.
P/E (forward): same as P/E, but using analysts' estimated earnings per share for the next year.
Same as P/E, using estimated future earnings.
PEG: the P/E divided by the expected earnings growth rate — relates how expensive the stock is to how fast it's expected to grow.
Not enough data (requires future growth estimates).
Debt/Equity: how much debt the company carries per dollar of shareholder equity — measures how leveraged the balance sheet is.
Low leverage: conservative balance sheet, less risk if interest rates rise.
Net margin: what percentage of each dollar of revenue ends up as net profit, after all costs.
Low margin: the business has little cushion if costs rise.
Dividend: what percentage of the stock's price is paid out in cash to shareholders each year.
Doesn't pay dividends: reinvests earnings into growth instead of distributing them.
Beta: how volatile the stock is compared to the overall market (S&P 500 = 1.0).
More volatile than the market: higher potential gain, but also higher potential loss.
General reference ranges, do not vary by sector. Third-party data; may be incomplete. Not investment advice.
💰 Financial Statements (last 3 quarters)
💰 Financial Statements (last 3 quarters)
What this chart shows
- Japanese candlesticks: green when the period's close is higher than its open, red when it's lower.
- Volume: bars colored the same as the candle for that period.
- RSI (14): bottom line with reference levels at 70 (overbought) and 30 (oversold) — the same indicator the daily scanner uses.
- Dotted line on top: the high of the last 20 periods, the same reference the scanner uses to detect breakouts.
Third-party market data, for informational purposes. Not investment advice — read the disclaimer.